For the past decade, we have accumulated expertise covering the entire product development process, ranging from basic research, T cell engineering and development, and preclinical/clinical trial and assessment.
Led by industry and academic experts from our base in Singapore, we are dedicated to the commercialization and continued development of our immunotherapy products in the World.
Scientific Founder & Chairman
Prof Antonio Bertoletti is named top 0.1% Hepatitis B Expert in the World over the past 10 years (Expertscape in 2019). He was the Director of Infection and Immunity Program at the Singapore Institute for Clinical Sciences (SICS) under A*STAR until 2013. Currently, he is a professor in the Division Emerging Infectious Diseases at Duke-NUS Graduate Medical School. Prof Antonio was trained as a specialist in Infectious Diseases and has always been interested in immunological control of persistent viral infections, particularly Hepatitis B (HBV). His current research focuses on the development of new immunological based therapies (TCR-redirected T cells, HLA-peptide specific antibodies) for the treatment of HBV and Hepatocellular carcinoma (HCC), and the characterization of human intra-sinusoidal hepatic immune system. Prof Antonio and his team have received the 1st Prize Award based on the first in the world using HBV-specific TCR-T for liver cancer. He has been holding scientific advisor role for Gilead, MedImmune, Vir Biotechnology and Janssen. To learn more about his lab: http://www.bertolettilab.com
Dr Peng obtained his PhD degree from National University of Singapore (NUS) and holds Adjunct Associate Professor at NUS, he has over 18 years working experience at A*STAR holding senior positions including Head of Division & Senior Scientist, Deputy Director of the Strategic Planning for China. With over two decades of experience in R&D and team management, he has accumulated tens of millions research grants and funding from industry partners.
COO & CMO
Dr Wang is a medical doctor. She obtained her PhD degree from National University of Singapore (NUS), and has over 20 years experience in the field of oncology in biopharmaceutical industry, clinical practice and translational medical research. She led the Asia Pacific medical team for the successful pre-launch and launch of VENTANA PD-L1 assays (SP142 and SP263) at Roche Diagnostics APAC. She has driven the advanced CD30 CAR-T cell therapy into clinical trials and led the FDA IND clearance to treat lymphoma patients at Tessa Therapeutics.
Director of Technology and Manufacturing
Dr Koh was an A*STAR scholar and obtained her PhD in Medical Science from Karolinska Institute, Sweden in 2013. She was a post-doctoral fellow in the laboratory of Professor Antonio Bertoletti at Singapore Institute for Clinical Sciences (SICS) of A*STAR. Her current R&D and product development interests are focused on T-cell immunotherapy and the immuno-pathogenesis of hepatitis B virus infection. Since 2017, she has led Lion TCR's efforts on product development and process optimisation in T cell immuno-therapy and the immuno-pathogenesis of hepatitis B virus infection.
Associate Director of Quality
Jiun Min has 10 years of working experience in biopharmaceutical enterprises, covering professional experience in GMP production, quality control (QC), environmental monitoring, product release testing, quality assurance (QA) where he has successfully obtained GMP certification and approval for product registration. He is responsible for the construction and operation of the GMP quality management system, product release and QA at Lion TCR.
Director of Research and Development
Dr Wai was an A*STAR scholar with over 15 years of experience in immunology research, in the fields of transplantation, cancer and HBV immunopathogenesis. She obtained her Ph.D. in Immunology from Stanford University, U.S.A. in 2010, focusing on immune cell interactions in liver transplantation and cancer. Since 2017, Dr Wai has led Lion TCR’s efforts to expand the TCR library and pipeline project.
Associate Director of Strategy and Business Development
Dr Zhou Yi was Singapore MOE scholar and obtained his PhD in Biochemistry Department from NUS in 2016. Dr Zhou was founding member of GenEros Biopharma,and act as Associate Director of Biology Department. He established bio-assay platform for drug efficacy screening, which lead to an IND enabling and FDA approval for phase I clinical trial. Dr Zhou also lead the development of antibody based drugs, engaged in license in of new pipelines and IND application in CDE (China).
Dr Anthony has over 9 years of extensive experience in immunology and virology at Dr. Antonio Bertoletti’s laboratory. He obtained his Ph.D. from the National University of Singapore in 2012 and is experienced in the selection of antigen targets in viral infection-related cancer, the construction of T cell receptors, and in conducting preclinical research in animal models.